Ashish Sharma

Kidney doctor & Physician @MNCLHD| PhD @unimelb @TheRMH | Renal bone disease| Views my own @[email protected]

[Joel M. Topf, MD FACP @kidney_boy]

But the subgroup analysis showed no signal with MRAs! I guess we should trust the meta-analysis. 50,000 people don't lie

[Swapnil Hiremath @hswapnil.medsky.social @hswapnil]

Cristina is back
Follow @CristinaDeReins

(@NephroSeeker was hacked with zero help from @Support )

#NephJC #AskRenal

[Brendon Neuen @brendonneuen]

New analysis of the ASCEND-ND trial:

Iron deficiency defined by low TSAT, but not low ferritin levels, is associated with increased risk of heart failure and cardiovascular death in CKD, independent of hemoglobin.

New in #EJHF: https://t.co/H93GdkCEsT

[Brendon Neuen @brendonneuen]

*Late-breaking clinical trials announced for @ERAkidney*

Looking forward to sharing main results from FIND‑CKD, plus:

- Detailed analyses of effects in ~900 pts with glomerular disease
- An IPD meta‑analysis across the spectrum of CKD

📍5 June, Glasgow #ERA26

[Maria Jose Soler @PepaSolerR]

RAAS blockade in the kidney Life-Cycle -Terrific work & Mentoring by @diego_moriconi @ClaraGCarro @yulnunezvill @KatherineTuttl8 #correaRotter @ERAkidney - https://t.co/Gb8A0xnwmD

[NDT @NDTsocial]

😩The updated global burden of chronic kidney disease:

one death every 20 seconds

🆓https://t.co/zlsw7IURNz

@ERAkidney @OxfordJournals

[Stroke AHA/ASA @StrokeAHA_ASA]

2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association https://t.co/ztmfxD3mBZ

[MaFer Zavala @Mafer_ZavalaM]

💫 2025 was a landmark year for glomerular diseases!
Major advances for GN treatment, from IgAN and lupus nephritis to rare diseases like C3G.

Can’t wait for what’s coming next!
And the eGFR outcomes!
Hope these new treatment options are soon available in our countries.

#2025 #GlomerularDiseases #IgAN #LN #C3G #GlomLove

[Sourabh Sharma @iamnephrologist]

“Permissive Hyperkalemia”

🔆Usual approach of aggressive hyperK measures not always necessary in mild or chronic hyperK

💥Permissive hyperkalemia proposes
balanced approach toward K management, looking into clinical diagnosis, drug history, symptomatology,
vitals, ECG changes, & urine output

🔗 https://t.co/8z6cpFucWk

[Hector Madariaga, MD FASN 🇲🇽 @HecmagsMD]

A nephrologist gives a kidney, receives hope.
Very inspiring! A true shero and one of my favorite people in the world... 🙌
@AnnaGaddy
https://t.co/QGjZ9l9Bzp

[Dr Priti MD,FASN🇮🇳 (प्रिति) @priti899]

🔥Check out the Indian guidelines for Interventional Nephrology for dialysis access and kidney biopsy ✔️ recently published in @indian journal of Nephrology
https://t.co/taB0VW3Wvk

[Jasmine Sethi @JasmineNephro]

❤️‍🩹Heart Failure drugs use according to CKD stage

https://t.co/JyML9X5VRG

@AJKDonline

[Brendon Neuen @brendonneuen]

Fantastic to see CONFIDENCE trial results presented at #ERA25 and in @NEJM

Prevention of CV events, esp. heart failure, is probably most compelling rationale for rapid initiation of combo therapy in CKD/T2D, with benefits on kidney failure accruing gradually over time

[Rajiv Agarwal MD, MS @AgarwalRajivMD]

More than 50% reduction in uacr with combo and about 30% with each component that is empagliflozin and finerenone. Time to consider simultaneous initiation of combination therapy in ckd and t2d as in hfref and stage 2 hypertension.

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

Schematic view illustrating the events leading to crescent 🌙 formation #Nephpearls
(a) Normal glomerulus
(b) Glomerular disease leads to gaps or holes in the glomerular basement membrane (GBM), resulting in
(c) proliferation of parietal epithelial cells and ultimately
(d) fibrocellular crescent formation

👉 Source: @ACPIMPhysicians Medicine Book, Chapter on Glomerular Diseases by Raimund Pichler and @StuartShankland

[Novi Yanti Sari @slumberbell]

Pooled analysis of DAPA-HF & DELIVER:

📍730 pts (6.7%) had severe HF
📍Dapagliflozin ⬇️ risk in both severe (HR 0.73) & nonsevere HF (HR 0.79)
📍NNT = 14
📍Safe, effective across LVEF

🔗 https://t.co/ONSdbwQc8v

#JACCHF @RInciardi @mvaduganathan @MkosiborodMD @scottdsolomon

[Brendon Neuen @brendonneuen]

Rationale and Design of the RENAL LIFECYCLE Trial Assessing the Effect of Dapagliflozin on Cardiorenal Outcomes in Severe Chronic Kidney Disease

~1500 patients (GFR<25, dialysis, or transplant GFR<45)
PEP: HHF or all-cause mortality (dialysis) and ESKD

https://t.co/nxNCk5YH2w

[Edgar V. Lerma 🇵🇭 @edgarvlermamd]

If a patient developed a UTI after initiation of SGLT2 inhibitor (SGLT2i) therapy, how likely are you going to re-challenge or not ... what factors would influence your decision ⁉️
#Nephpearls #AskRenal

[Sanjeev Sethi @SethiRenalPath]

Basics of Glomerulonephritis (GN). GBM is key.

All patterns can be explained by glomerular basement membrane (GBM) & type of injury.

Let’s do one at a time

CRESCENTIC GN

1. Results from breach/break of GBM (red arrow)

2. Injury is sudden & severe

Eg-ANCA & anti-GBM GN

[Vandana Dua Niyyar @vandyniyyar]

Superb job @Nephro_Sparks @anna_burgner @atlee_baker @koyaljainMD @bharvioza @Kidneylsu @AdinaVoiculescu THANK YOU @ASNKidney @proychaudhuryMD for ur vision & support🙏The 1st step to optimize dialysis access care starts with training our next generation! https://t.co/LrzY00b670